November 18, 2026 · American heart journal · DOI: 10.1016/j.ahj.2026.107661

Drug Development in Pediatric Heart Failure: Current Landscape and Future Directions.

Listen to this summary

This review examines the current landscape of pediatric heart failure drug development, where most treatments are adult drugs used off-label and regulatory guidance is limited. The authors ask how drug development can shift toward a mechanism-of-action-driven approach and a new high-level phenotype classification, given the diverse pathophysiology of pediatric HF. They propose that pharmacokinetic extrapolation, bridging biomarkers, adaptive trial designs, and harmonized regulatory frameworks offer promising paths forward in the absence of validated surrogate endpoints.

Priya Sekar, Patricia E Pizzato, Ulrika Mattsson, Naomi Bartley, Hongjian Li, Maria Learoyd, Angeliki Siapkara, Pamela Zee, Angela Lorts, Kevin P Daly

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play